Trial Search Results
A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis.
Stanford is currently not accepting patients for this trial.
- Biological: Lebrikizumab
- Drug: Placebos
- Male or female, 18 years or older.
- Chronic AD as defined by Hanifin and Rajka (1980) that has been present for ≥1 year
before the screening visit .
- Eczema Area and Severity Index (EASI) score ≥16 at the screening and the baseline
- Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the screening and
the baseline visit.
- ≥10% body surface area (BSA) of AD involvement at the screening and the baseline
- Treatment with any of the following agents within 4 weeks prior to the baseline visit:
- Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids,
cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine,
- Phototherapy and photochemotherapy (PUVA) for AD.
- Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)
within 1 week prior to the baseline visit.
- Treatment with:
- An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is
longer, prior to the baseline visit.
- Dupilumab within 3 months prior to baseline visit.
- Cell-depleting biologics, including rituximab, within 6 months prior to the baseline
- Other biologics within 5 half-lives (if known) or 16 weeks prior to baseline visit
(whichever is longer).
- Use of prescription moisturizers within 7 days of the baseline visit.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study